Pondicherry Journal of Nursing

Register      Login

VOLUME 13 , ISSUE 1 ( January-March, 2020 ) > List of Articles

Drug Profile

Esketamine Nasal Spray

Mohamed SJ Farhana, Subbarayan Dhivagar, Subramaniyan Prabavathy

Keywords : Esketamine, Nasal spray, Treatment-resistant depression

Citation Information : Farhana MS, Dhivagar S, Prabavathy S. Esketamine Nasal Spray. 2020; 13 (1):13-15.

DOI: 10.5005/jp-journals-10084-12137

License: CC BY-NC 4.0

Published Online: 20-07-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Esketamine is the newer drug in psychiatry with high efficacy. Esketamine (s-enantiomer of ketamine) was approved by the FDA on March 5, 2019, to treat treatment-resistant depression. Esketamine is delivered through nasal spray. Nasal spray is the fast-acting drug. It can be used to treat treatment-resistant depression. Each device contains 28 mg. Esketamine increases dopamine activity in the brain. It is contraindicated for patient with aneurysmal vascular disease, arteriovenous malformation, intracerebral hemorrhage, children, pregnant mothers, and lactating mothers.


PDF Share
  1. Molero P, Ramos-Quiroga JA, Martin-Santos R, et al. Antidepressant efficacy and tolerability of ketamine and Esketamine: a critical review. CNS Drugs 2018;32(5):411–420. DOI: 10.1007/s40263-018-0519-3.
  2. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 2017;78(7):e852–e857. DOI: 10.4088/JCP.17f11738.
  3. Bahr R, Lopez A, Rey JA. Intranasal Esketamine (Spravato™) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T 2019;44(6):340–375.
  4. Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal Esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018;17(1):620–630. DOI: 10.1176/appi.ajp.2018.17060720.
  5. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015;72(4):334–341. DOI: 10.1001/jamapsychiatry.2014.2502.
  6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163(11): 1905–1917. DOI: 10.1176/ajp.2006.163.11.1905.
  7. World Health Organization, Media Centre, Depression Fact Sheet, Updated 22 March. 2018. Accessed December 26, 2018.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.